CODAGENIX INC
CODAGENIX INC is a federal contractor, registered under UEI TEMNL437K2F1 and CAGE code 5D8K5. It has been awarded $30,043,342 across 18 federal contracts. Primary work spans Unknown NAICS, Research and Development in Biotechnology (except Nanobiotechnology), and Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Department Of Agriculture.
Contact Information
Registration and classification details
Registration
UEI Code
TEMNL437K2F1CAGE Code
5D8K5Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
Codagenix Inc. specializes in the design, development, and clinical evaluation of live attenuated viral vaccines, with a focused expertise in Phase 2b efficacy trials for infectious disease therapeutics. The company leverages proprietary virology platforms to engineer novel vaccine candidates, condu...
Codagenix Inc. specializes in the design, development, and clinical evaluation of live attenuated viral vaccines, with a focused expertise in Phase 2b efficacy trials for infectious disease therapeutics. The company leverages proprietary virology platforms to engineer novel vaccine candidates, conducting rigorous preclinical and clinical studies to assess immunogenicity, safety, and protective efficacy in human populations. Their technical capabilities include viral vector optimization, attenuated strain selection, GCP-compliant trial execution, and regulatory-grade data package development for biologics licensing. Codagenix differentiates itself through its precision attenuation technologies and end-to-end pipeline management from candidate selection through clinical proof-of-concept, particularly for respiratory pathogens like SARS-CoV-2. The contractor has delivered research and development services to the Department of Health and Human Services, primarily supporting advanced-stage vaccine evaluation under targeted public health initiatives. Their engagement with HHS reflects a strategic alignment with federal biodefense and pandemic preparedness objectives, where they provide specialized biotechnology R&D to advance candidate vaccines through clinical development milestones. Codagenix operates exclusively within the 541714 NAICS category, which encompasses non-nanobiotechnology biotech research and development. This positions them as a niche player in infectious disease vaccine innovation, with deep specialization in live attenuated virus platforms and clinical trial execution for viral vaccines. Their market focus is squarely on translational biotechnology, bridging laboratory discovery with regulatory-ready clinical data for government-funded health security programs. As a small business structured as a 2L entity based in Farmingdale, New York, Codagenix maintains a lean, mission-driven operational model focused on high-impact biotech R&D. The company currently holds no federal certifications, but its work is grounded in strict adherence to clinical trial standards, biosafety protocols, and FDA-aligned regulatory pathways. Its geographic footprint is centered in the New York biotech corridor, supporting its role as a specialized contractor for federal health research initiatives.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
